Cargando…

Clinical application value of metagenomic second-generation sequencing technology in hematologic diseases with and without transplantation

INTRODUCTION: Hematological patients are at risk of infections. It is unknown whether the pathogenic microbial spectrum differs between HSCT and non-HSCT patients, and whether metagenomic next-generation sequencing (mNGS) of peripheral blood can be used as a substitute test specimen such as alveolar...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xia, Wang, Fang, Yu, Jifeng, Jiang, Zhongxing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10311908/
https://www.ncbi.nlm.nih.gov/pubmed/37396304
http://dx.doi.org/10.3389/fcimb.2023.1135460
_version_ 1785066849053966336
author Zhang, Xia
Wang, Fang
Yu, Jifeng
Jiang, Zhongxing
author_facet Zhang, Xia
Wang, Fang
Yu, Jifeng
Jiang, Zhongxing
author_sort Zhang, Xia
collection PubMed
description INTRODUCTION: Hematological patients are at risk of infections. It is unknown whether the pathogenic microbial spectrum differs between HSCT and non-HSCT patients, and whether metagenomic next-generation sequencing (mNGS) of peripheral blood can be used as a substitute test specimen such as alveolar lavage. METHODS: A retrospective study was conducted to evaluate the clinical application value of mNGS in hematological patients with and without HSCT. RESULTS: Viruses were prevalent pathogens in both non-HSCT (44%) and HSCT (45%) patients, chiefly human cytomegalovirus and Epstein–Barr virus. In non-HSCT patients, Gram-negative bacilli accounted for 33% (predominantly Klebsiella pneumonia), and Gram-positive cocci accounted for 7% (predominantly Enterococcus faecium) of pathogens. However, in HSCT patients, Gram-negative bacilli accounted for 13% (predominantly Stenotrophomonas maltophilia), and Gram-positive cocci accounted for 24% (predominantly Streptococcus pneumonia) of pathogens. Mucor was the most common fungu s in two groups. The positive rate of pathogens by mNGS was 85.82%, higher than conventional detection (20.47%, P < 0.05). Mixed infection accounted for 67.00%, among which the mixed infection of bacteria and virus (25.99%) was the most common. 78 cases had pulmonary infection, the positive rate of traditional laboratory tests was 42.31% (33/78), and of mNGS in peripheral blood was 73.08% (57/78), showing a statistical difference (P = 0.000). The non-HSCT patients had a higher frequency of Klebsiella pneumonia (OR=0.777, 95% CI, 0.697-0.866, P = 0.01) and Torque teno virus (OR=0.883, 95% CI, 0.820-0.950, P = 0.031) infections than HSCT patients, while the rates of Streptococcus pneumonia (OR=12.828, 95% CI, 1.378-119.367, P = 0.016), Candida pseudosmooth (OR=1.100, 95% CI, 0.987-1.225, P = 0.016), human betaherpesvirus 6B (OR=6.345, 95% CI, 1.105-36.437, P = 0.039) and human polyomavirus 1 (OR=1.100, 95% CI, 0.987-1.225, P = 0.016) infections were lower. Leishmania could be detected by mNGS. CONCLUSION: mNGS of peripheral blood can be used as a substitute test method for hematological patients with pulmonary infection, the detection rate of mixed infections by mNGS was high, and mNGS has high clinical recognition rate and sensitivity in pathogen detection, and provides a basis for guiding the anti-infective treatment in hematological diseases with symptoms such as fever.
format Online
Article
Text
id pubmed-10311908
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-103119082023-07-01 Clinical application value of metagenomic second-generation sequencing technology in hematologic diseases with and without transplantation Zhang, Xia Wang, Fang Yu, Jifeng Jiang, Zhongxing Front Cell Infect Microbiol Cellular and Infection Microbiology INTRODUCTION: Hematological patients are at risk of infections. It is unknown whether the pathogenic microbial spectrum differs between HSCT and non-HSCT patients, and whether metagenomic next-generation sequencing (mNGS) of peripheral blood can be used as a substitute test specimen such as alveolar lavage. METHODS: A retrospective study was conducted to evaluate the clinical application value of mNGS in hematological patients with and without HSCT. RESULTS: Viruses were prevalent pathogens in both non-HSCT (44%) and HSCT (45%) patients, chiefly human cytomegalovirus and Epstein–Barr virus. In non-HSCT patients, Gram-negative bacilli accounted for 33% (predominantly Klebsiella pneumonia), and Gram-positive cocci accounted for 7% (predominantly Enterococcus faecium) of pathogens. However, in HSCT patients, Gram-negative bacilli accounted for 13% (predominantly Stenotrophomonas maltophilia), and Gram-positive cocci accounted for 24% (predominantly Streptococcus pneumonia) of pathogens. Mucor was the most common fungu s in two groups. The positive rate of pathogens by mNGS was 85.82%, higher than conventional detection (20.47%, P < 0.05). Mixed infection accounted for 67.00%, among which the mixed infection of bacteria and virus (25.99%) was the most common. 78 cases had pulmonary infection, the positive rate of traditional laboratory tests was 42.31% (33/78), and of mNGS in peripheral blood was 73.08% (57/78), showing a statistical difference (P = 0.000). The non-HSCT patients had a higher frequency of Klebsiella pneumonia (OR=0.777, 95% CI, 0.697-0.866, P = 0.01) and Torque teno virus (OR=0.883, 95% CI, 0.820-0.950, P = 0.031) infections than HSCT patients, while the rates of Streptococcus pneumonia (OR=12.828, 95% CI, 1.378-119.367, P = 0.016), Candida pseudosmooth (OR=1.100, 95% CI, 0.987-1.225, P = 0.016), human betaherpesvirus 6B (OR=6.345, 95% CI, 1.105-36.437, P = 0.039) and human polyomavirus 1 (OR=1.100, 95% CI, 0.987-1.225, P = 0.016) infections were lower. Leishmania could be detected by mNGS. CONCLUSION: mNGS of peripheral blood can be used as a substitute test method for hematological patients with pulmonary infection, the detection rate of mixed infections by mNGS was high, and mNGS has high clinical recognition rate and sensitivity in pathogen detection, and provides a basis for guiding the anti-infective treatment in hematological diseases with symptoms such as fever. Frontiers Media S.A. 2023-06-16 /pmc/articles/PMC10311908/ /pubmed/37396304 http://dx.doi.org/10.3389/fcimb.2023.1135460 Text en Copyright © 2023 Zhang, Wang, Yu and Jiang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cellular and Infection Microbiology
Zhang, Xia
Wang, Fang
Yu, Jifeng
Jiang, Zhongxing
Clinical application value of metagenomic second-generation sequencing technology in hematologic diseases with and without transplantation
title Clinical application value of metagenomic second-generation sequencing technology in hematologic diseases with and without transplantation
title_full Clinical application value of metagenomic second-generation sequencing technology in hematologic diseases with and without transplantation
title_fullStr Clinical application value of metagenomic second-generation sequencing technology in hematologic diseases with and without transplantation
title_full_unstemmed Clinical application value of metagenomic second-generation sequencing technology in hematologic diseases with and without transplantation
title_short Clinical application value of metagenomic second-generation sequencing technology in hematologic diseases with and without transplantation
title_sort clinical application value of metagenomic second-generation sequencing technology in hematologic diseases with and without transplantation
topic Cellular and Infection Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10311908/
https://www.ncbi.nlm.nih.gov/pubmed/37396304
http://dx.doi.org/10.3389/fcimb.2023.1135460
work_keys_str_mv AT zhangxia clinicalapplicationvalueofmetagenomicsecondgenerationsequencingtechnologyinhematologicdiseaseswithandwithouttransplantation
AT wangfang clinicalapplicationvalueofmetagenomicsecondgenerationsequencingtechnologyinhematologicdiseaseswithandwithouttransplantation
AT yujifeng clinicalapplicationvalueofmetagenomicsecondgenerationsequencingtechnologyinhematologicdiseaseswithandwithouttransplantation
AT jiangzhongxing clinicalapplicationvalueofmetagenomicsecondgenerationsequencingtechnologyinhematologicdiseaseswithandwithouttransplantation